Dr Karunakar Sukuru of Catalent explains how lipid-based softgels address physiological barriers to oral peptide delivery as approvals increase.
Karunakar Sukuru
Advertisement
Karunakar (Karu) Sukuru, RPh, PhD, is segment vice president of global product development and innovation at Catalent Pharma Solutions.
Articles by Karunakar Sukuru
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
2
FDA Approves On-Body Injector Induction for Skyrizi in Crohn's Disease
3
Zymeworks Licenses DLL3-Targeted Trispecific T-Cell Engager ZW209 to Roche in Deal Worth Up to $813 Million
4
Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 2: CMC and Regulations
5